TY - JOUR
T1 - Impact of MR-based attenuation correction on neurologic PET studies
AU - Su, Yi
AU - Rubin, Brian B.
AU - McConathy, Jonathan
AU - Laforest, Richard
AU - Qi, Jing
AU - Sharma, Akash
AU - Priatna, Agus
AU - Benzinger, Tammie L.S.
N1 - Funding Information:
Funding for this study was provided by The Charles F. and Joanne Knight Alzheimer's Research Initiative, NIH/NIA P50 AG05681, NIH/NIA P01AG026276, NIH/NIA P01AG003991, NIH/NIA P50 AG05681, NIH 5P30NS048056, and NIH 2UL1TR000448. Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) provided the florbetapir tracer for the study and partial funding support of the scan acquisitions. Dr. Priatna is a full-time employee of Siemens Medical Solutions, USA. The industry sponsors had no role in the design and execution of this study. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
COPYRIGHT © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Hybrid PET and MR scanners have become a reality in recent years, with the benefits of reduced radiation exposure, reduction of imaging time, and potential advantages in quantification. Appropriate attenuation correction remains a challenge. Biases in PET activity measurements were demonstrated using the current MR-based attenuation-correction technique. We aimed to investigate the impact of using a standard MR-based attenuation correction technique on the clinical and research utility of a PET/MR hybrid scanner for amyloid imaging. Methods: Florbetapir scans were obtained for 40 participants on a hybrid scanner with simultaneous MR acquisition. PET images were reconstructed using both MR-and CT-derived attenuation maps. Quantitative analysis was performed for both datasets to assess the impact of MR-based attenuation correction to absolute PET activity measurements as well as target-to-reference ratio (SUVR). Clinical assessment was also performed by a nuclear medicine physician to determine amyloid status based on the criteria in the Food and Drug Administration prescribing information for florbetapir. Results: MR-based attenuation correction led to underestimation of PET activity for most parts of the brain, with a small overestimation for deep brain regions. There was also an overestimation of SUVRs with cerebellar reference. SUVR measurements obtained from the 2 attenuation-correction methods were strongly correlated. Clinical assessment of amyloid status resulted in identical classification as positive or negative regardless of the attenuation-correction methods. Conclusion: MR-based attenuation correction causes biases in quantitative measurements. The biases may be accounted for by a linear model, although the spatial variation cannot be easily modeled. The quantitative differences, however, did not affect clinical assessment as positive or negative.
AB - Hybrid PET and MR scanners have become a reality in recent years, with the benefits of reduced radiation exposure, reduction of imaging time, and potential advantages in quantification. Appropriate attenuation correction remains a challenge. Biases in PET activity measurements were demonstrated using the current MR-based attenuation-correction technique. We aimed to investigate the impact of using a standard MR-based attenuation correction technique on the clinical and research utility of a PET/MR hybrid scanner for amyloid imaging. Methods: Florbetapir scans were obtained for 40 participants on a hybrid scanner with simultaneous MR acquisition. PET images were reconstructed using both MR-and CT-derived attenuation maps. Quantitative analysis was performed for both datasets to assess the impact of MR-based attenuation correction to absolute PET activity measurements as well as target-to-reference ratio (SUVR). Clinical assessment was also performed by a nuclear medicine physician to determine amyloid status based on the criteria in the Food and Drug Administration prescribing information for florbetapir. Results: MR-based attenuation correction led to underestimation of PET activity for most parts of the brain, with a small overestimation for deep brain regions. There was also an overestimation of SUVRs with cerebellar reference. SUVR measurements obtained from the 2 attenuation-correction methods were strongly correlated. Clinical assessment of amyloid status resulted in identical classification as positive or negative regardless of the attenuation-correction methods. Conclusion: MR-based attenuation correction causes biases in quantitative measurements. The biases may be accounted for by a linear model, although the spatial variation cannot be easily modeled. The quantitative differences, however, did not affect clinical assessment as positive or negative.
KW - Amyloid imaging
KW - Attenuation correction
KW - PET/MR
UR - http://www.scopus.com/inward/record.url?scp=84973623367&partnerID=8YFLogxK
U2 - 10.2967/jnumed.115.164822
DO - 10.2967/jnumed.115.164822
M3 - Article
C2 - 26823562
AN - SCOPUS:84973623367
SN - 0161-5505
VL - 57
SP - 913
EP - 917
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 6
ER -